Loading provider…
Loading provider…
Neurology Physician in Baltimore, MD
NPI: 1245395474Primary Practice Location
JOHNS HOPKINS HOSPITAL, THE
1800 Orleans St, Baltimore, MD
Primary Employer
Jhu - Neurology
hopkinsmedicine.org
HQ Phone
Get MD, MCR Ellen's Phone Numberphone_androidMobile
Get MD, MCR Ellen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMD State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 20 | 29 |
Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.
Authors: Darin Okuda, Douglas Goodin, Daniel Pelletier, Bruce Cree, Emmanuelle Waubant
Journal: Neurology
Publication Date: 2011-01-26
Demyelinating events in early multiple sclerosis have inherent severity and recovery.
Authors: E Mowry, M Pesic, B Grimes, S Deen, P Bacchetti, E Waubant
Publication Date: 2009-02-18
Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort.
Authors: Hu, Chen, Dewey, Blake E, Mowry, Ellen M, Fitzgerald, Kathryn C
Journal: Mult Scler
Publication Date: 2023-01-24
Lead Sponsor: Johns Hopkins University
Collaborators: Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Intervention / Treatment: OTHER: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, OTHER: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
Lead Sponsor: University of Texas Southwestern Medical Center
Collaborators: Biogen
Intervention / Treatment: DRUG: Placebo, DRUG: Tecfidera
Lead Sponsor: Johns Hopkins University
Collaborators: University of Pennsylvania, University of Rochester, University of California, San Francisco, Yale University, Stanford University, Columbia University, The Cleveland Clinic, Swedish Medical Center, Oregon Health and Science University, University of Virginia, Washington University School of Medicine, Icahn School of Medicine at Mount Sinai, Anne Arundel Health System Research Institute, University of Massachusetts, Worcester, Dignity Health
Intervention / Treatment: DRUG: Vitamin D3